Open AccessResistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission
Author(s) -
Scott C. Olson,
Nicole NgoGiangHuong,
Ingrid Beck,
Wenjie Deng,
Paula Britto,
David E. Shapiro,
Roger E. Bumgarner,
James I. Mullins,
Russell B. Van Dyke,
Gonzague Jourdain,
Lisa M. Frenkel
Publication year - 2015
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000737
Subject(s) - zidovudine , pyrosequencing , virology , human immunodeficiency virus (hiv) , transmission (telecommunications) , lentivirus , medicine , drug resistance , sida , viral disease , immunology , biology , genetics , computer science , gene , telecommunications
To prevent mother-to-child-transmission of HIV-1, the 2010 WHO guidelines recommended prenatal zidovudine (ZDV) monotherapy (option A). To determine if ZDV monotherapy selects for HIV resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. ZDV-resistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%). These data raise the question whether women administered ZDV monotherapy for prevention of mother-to-child-transmission could have higher risk of virologic failure when later started on combination antiretroviral therapy, as has been demonstrated following single-dose nevirapine prophylaxis.